Rachel Butler
President and Board Director

As President of the Catalytic Impact Foundation, Rachel Butler has extensive experience and expertise analyzing, evaluating, and investing in early- and mid-stage companies in the life sciences and healthcare industry. Since 2016, she has reviewed hundreds of such companies and served as a team leader, overseeing and managing the research, analysis, and investment processes, to select companies for presentation and/or investment, beginning at Cavendish Global and then at Catalytic Impact Foundation. She is a lead member of the investment team that invested in the CIF portfolio of innovative healthcare companies. Previously, she served as co-founder and Editor-in-Chief of Asthma Magazine, a patient education publication for asthma and allergy. The magazine was used by the NHLBI to educate participants in its nationwide children’s asthma (CAMP) study; by Merck to launch its first-in-class asthma drug, Singulair; and by the American Lung Association, the American Academy of Asthma, Allergy and Immunology, the National Association of School Nurses, health maintenance organizations, disease management companies, and private practitioners throughout the country, to educate their patients about the condition. Subsequently, she guided the company through its acquisition by Elsevier Health Sciences, a leading publisher of medical journals, where she continued as Editor-in-Chief for five years. She is a graduate of St. Lawrence University, a trustee and treasurer of the Ross Conservation Trust, and is an avid skier, sailor, tennis player. She is married with four children and lives near Boston, MA.